FGFR2 and cholangiocarcinoma: The finding of recurrent missense mutations in the FGFR2 gene is of particular clinical interest given the therapeutic implications for activating mutations in this gene for treatment of solid tumors, including CCA, with FGFR inhibitors [28] (classified as level 4 (compelling biological evidence) according to OncoKB search), as well as the reported finding of recurrent FGFR2-fusions in 22% of pancreatic ITPNs [3].